Lung Cancer Clinical Trial
A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer
Summary
The purpose of this study is to determine whether BIIB022, Paclitaxel and Carboplatin are effective in the treatment of Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer.
Eligibility Criteria
Inclusion Criteria:
Age >/= 18 years old
Treatment-naive Stage IIIB/IV Non-Small Cell Lung Cancer
ECOG Performance Status 0 or 1
Exclusion Criteria:
History of another primary cancer within 3 years
Any prior or concurrent investigational or standard therapy for treatment of NSCLC
Prior anti-IGF-1R therapy
Unstable diabetes
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Los Angeles California, , United States
San Diego California, , United States
Denver Colorado, , United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.